Clinical Trial

Assessment of FibbroScan in Diagnosing MASLD Among the Chinese Population With Obesity

Study acronym: MASLD
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 6, 2024 (before its estimated March 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The non-invasive evaluation of liver steatosis and fibrosis with FibroScan is a routinely procedure in clinical practice for people with obesity. However, there are still considerable uncertainties regarding the potential influence of confounding factors and the optimal application of cut-off values for obesity. The goal of this observational study is to learn about the optimal application of cut-off values of for Chinese people with obesity.
Trial Details
NCT Number NCT06720766
Lead Sponsor The Third People's Hospital of Chengdu
Conditions Fatty Liver Disease
Enrollment 600 participants
Start Date 2023-10-24
Primary Completion 2025-03-31 (estimated)
Study Completion 2025-03-31 (estimated)
Updated on ClinicalTrials.gov 2024-12-06